Antioxidant properties of minocycline: Neuroprotection in an oxidative stress assay and direct radical-scavenging activity

Journal of Neurochemistry

Volumn 94, Issue 3, 2005, Pages 819-827

  Kraus, Richard L ^a   Pasieczny, Rodger ^a   Lariosa Willingham, Karen ^a   Turner, Mary S ^a   Jiang, Alice ^a   Trauger, John W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Deoxyribose degradation assay; Lipid peroxidation assay; Mixed neuronal cultures; Neurodegenerative diseases; Radical scavenging assay; Tetracyclines

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; 4 DODECYLPHENOL; ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMPICILLIN; APOMORPHINE; ASCORBIC ACID; BUTYLCRESOL; CHLORTETRACYCLINE; CLOZAPINE; DEFEROXAMINE; DEMECLOTETRACYCLINE; DOXYCYCLINE; EBSELEN; ESTRADIOL; FLURBIPROFEN; KANAMYCIN; MELATONIN; MINOCYCLINE; NALOXONE; NALTREXONE; NORPHENAZONE; PHENOL DERIVATIVE; PHENOTHIAZINE; PHENOXAZINE DERIVATIVE; RADICAL; TETRACYCLINE; TETRACYCLINE DERIVATIVE; THIOCTIC ACID; TROLOX C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BIOASSAY; BRAIN HOMOGENATE; CELL PROTECTION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG STRUCTURE; IN VITRO STUDY; LIPID PEROXIDATION; NERVE CELL CULTURE; NERVOUS SYSTEM INJURY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SCAVENGING SYSTEM;

ANIMALS; ANTIOXIDANTS; ANTIPYRINE; BENZOTHIAZOLES; CELL DEATH; CELLS, CULTURED; CEREBRAL CORTEX; CHROMANS; DEOXYRIBOSE; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO; FREE RADICAL SCAVENGERS; FREE RADICALS; GLUTAMIC ACID; INHIBITORY CONCENTRATION 50; L-LACTATE DEHYDROGENASE; LIPID PEROXIDATION; MINOCYCLINE; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PHENETHYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONIC ACIDS; VITAMIN E;

ANIMALIA;

EID: 23244453399     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03219.x     Document Type: Article

References (33)

1. Behl C. (2000) Vitamin E protects neurons against oxidative cell death in vitro more effectively than 17-β-estradiol and induces the transcription factor NF-κ-B. J. Neural Transm. 107, 393-407.
2. Blum D., Chtarto A., Tenenbaum L., Brotchi J. and Levivier M. (2004) Clinical potential of minocycline for neurodegenerative disorders. Neurobiol. Dis. 17, 359-366.
3. Callaway J. K., Beart P. M. and Jarrott B. (1998) A reliable procedure for comparison of antioxidants in rat brain homogenates. J. Pharmacol. Toxicol. Meth. 39, 155-162.
4. Caswell A. H. and Hutchison J. D. (1971) Selectivity of cation chelation to tetracyclines: evidence for special conformation of calcium chelate. Biochem. Biophys. Res. Comm. 43, 625-630.
5. Chen M., Ona V. O., Li M. et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6, 797-801.
6. Cimino R, Esposito F., Ammendola R. and Russo T. (1997) Gene regulation by reactive oxygen species. Curr. Top. Cell Regul. 35, 123-148.
7. Domercq M. and Matute C. (2004) Neuroprotection by tetracyclines. Trends Pharm. Sci. 25, 609-612.
8. Du Y., Ma Z., Lin S. et al. (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 14 669-14 674.
9. Friedlander R. M. (2003) Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 348, 1365-1375.
10. Gilgun-Sherki Y., Rosenbaum Z., Melamed E. and Offen D. (2002) Antioxidant therapy in acute central nervous system injury: current state. Pharmacol. Rev. 54, 271-284.
11. Gulcin I., Haci A. A. and Cesur M. (2005) Determination of in vitro antioxidant and radical scavenging activities of propofol. Chem. Pharm. Bull. 53, 281-285.
12. Gyamfi M. A. and Aniya Y. (2002) Antioxidant properties of Thonningianin A, isolated from the African medicinal herb, Thonningia sanguinea. Biochem. Pharmacol. 63, 1725-1737.
13. Kim D. O., Lee K. W., Lee H. J. and Lee C. Y. (2002) Vitamin C equivalent antioxidant capacity (VCEAC) of phenolic phytochemicals. J. Agric. Food Chem. 50, 3713-3717.
14. Lee S. M., Yune T. Y., Kim S. J., Kim Y. C., Oh Y. J., Markelonis G. J. and Oh T. H. (2004) Minocycline inhibits apoptotic cell death via attenuation of TNF-α expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures. J. Neurochem. 91, 568-578.
15. Lin S., Zhang Y., Dodel R., Farlow M. R., Paul S. M. and Du Y. (2001) Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci. Lett. 315, 61-64.
16. Lin S., Wei X., Xu Y., Yan C., Dodel R., Zhang Y., Liu J., Klaunig J. E., Farlow M. and Du Y. (2003) Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sci. 72, 1635-1641.
17. Martindale J. L. and Holbrook N. J. (2002) Cellular response to oxidative stress: signaling for suicide and survival. J. Cell Physiol. 192, 1-15.
18. Miller N. J. and Rice-Evans C. A. (1997) Factors influencing the antioxidant activity determined by the ABTS radical cation assay. Free Rad. Res. 26, 195-199.
19. Miyachi Y., Yoshioka A., Imamura S. and Niwa Y. (1986) Effect of antibiotics on the generation of reactive oxygen species. J. Invest. Dermatol. 86, 449-453.
20. Moosmann B. and Behl C. (1999) The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc. Natl Acad. Sci. USA 96, 8867-8872.
21. Moosmann B., Skutella T., Beyer K. and Behl C. (2001) Protective activity of aromatic amines and imines against oxidative nerve cell death. Biol. Chem. 382, 1601-1612.
22. Murphy T. H., Schnaar R. L. and Coyle J. T. (1990) Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J. 4, 1624-1633.
23. Pi R., Li W., Lee N. T., Chan H. H., Pu Y., Chan L. N., Sucher N. J., Chang D. C., Li M. and Han Y. (2004) Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. J. Neurochem. 91, 1219-1230.
24. Ratan R. R., Ryu H., Lee J., Mwidau A. and Neve R. L. (2002) In vitro model of oxidative stress in cortical neurons. Meth. Enzymol. 352, 183-190.
25. Stirling D. P., Khodarahmi K., Liu J., McPhail L. T., McBride C. B., Sleeves J. D., Ramer M. S. and Tetzlaff W. (2004) Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J. Neurosci. 24, 2182-2190.
26. Teng Y. D., Choi H., Onario R. C., Zhu S., Desilets F. C., Lan S., Woodard E. J., Snyder E. Y., Eichler M. E. and Friedlander R. M. (2004) Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc. Natl Acad. Sci. USA 101, 3071-3076.
27. Tikka T. M. and Koistinaho J. E. (2001) Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J. Immunol. 166, 7527-7533.
28. Tirosh O., Sen C. K., Roy S. and Packer L. (2000) Cellular and mitochondrial changes in glutamate-induced HT4 neuronal cell death. Neuroscience 97, 531-541.
29. Van Den Bosch L., Tilkin P., Lemmens G. and Robberecht W. (2002) Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13, 1067-1070.
30. Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D. K., Ischiropoulos H. and Przedborski S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771.
31. Xu L., Pagan S. C., Waller J. L., Edwards D. J., Borlongan C. V., Zheng J., Hill W. D., Feuerstein G. and Hess D. C. (2004) Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion- repertusion in rats. BMC Neurol. 4.
32. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P. H. and Koistinaho J. (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl Acad. Sci. USA 96, 13 496-13 500.
33. Zhu S., Stavrovskaya I. G., Drozda M. et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74-78.